Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
Holding AKRO?
Track your performance easily
AKRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.32 - $37.00
Previous Close$31.2
Volume53.51K
Average Volume (3M)549.87K
Market Cap
$2.19B
Enterprise Value$1.50B
Total Cash (Recent Filing)$717.25M
Total Debt (Recent Filing)$35.73M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Mar 13, 2025EPS Estimate
-$1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding69,799,148
10 Day Avg. Volume749,879
30 Day Avg. Volume549,873
Standard Deviation0.30
R-Squared0.00199
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.52
Forecast
1Y Price Target
$52.50Price Target Upside67.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Akero Therapeutics News
PremiumCompany Announcements
Akero Therapeutics Advances in MASH Treatment Trials
PremiumPre-Earnings
Is AKRO a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Clinical TrialsAkero announced the initiation of SYNCHRONY Outcomes, a Phase 3 trial assessing efruxifermin in MASH patients with compensated cirrhosis, fibrosis stage 4.
Drug DevelopmentEfruxifermin continues to be one of the most exciting MASH drug candidates in development from conversations and polling of physicians.
Financial HealthAkero reported Q2 2024 earnings, finishing the period with $848.3M in cash, cash equivalents, and short/long-term marketable securities, which is expected to fund operations into the second half of 2027.
Bears Say
Clinical ResultsThe Ph2b SYMMETRY trial results showed clinical failure of EFX versus placebo in fibrosis improvement.
Clinical TrialsA higher rate of discontinuations at Week 96 in the SYMMETRY trial compared to the HARMONY trial is expected due to more advanced enrolled patients.
Operational RisksKey risks to the rating and price target include unforeseen safety or tolerability issues and the inability to sufficiently fund operations.
---
Ownership Overview
3.27% Insiders
25.40% Mutual Funds
44.09% Other Institutional Investors
14.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKRO FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was $15.32 and its highest was $37.00 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Currently, no data Available
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 110 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on Nov 08, 2024. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.879 by -$0.171.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -$1.16.
How many shares outstanding does Akero Therapeutics Inc have?
Akero Therapeutics Inc has 69,799,150 shares outstanding.
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.879. Following the earnings report the stock price went down -1.204%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Among the largest hedge funds holding Akero Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Akero Therapeutics Inc’s shares valued at 49M.
---
Akero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.50 (67.60% Upside)
$52.50 (67.60% Upside)
Hedge Fund Trend
Increased
By 293.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $107.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.15%
12-Months-Change
Fundamentals
Return on Equity
-35.90%
Trailing 12-Months
Asset Growth
28.68%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
AKRO Stock 12 Month Forecast
Average Price Target
$52.50
▲(67.60% Upside)
Technical Analysis
Best Analysts Covering AKRO
1 Year
1 Year Success Rate
12/21 ratings generated profit
1 Year Average Return
+37.01%
reiterated a buy rating 5 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +37.01% per trade.
---